Ovarian hyperstimulation syndrome in the 21st century: The role of gonadotropin-releasing hormone agonist trigger and kisspeptin

Current Opinion in Obstetrics and Gynecology

Volumn 27, Issue 3, 2015, Pages 210-214

  Thomsen, Lise ^a   Humaidan, Peter ^a,b  

^a SKIVE REGIONAL HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

gonadotropin releasing hormone agonist; human chorionic gonadotropin; in vitro fertilization; kisspeptin; ovarian hyperstimulation syndrome

Indexed keywords

CHORIONIC GONADOTROPIN; GONADORELIN AGONIST; KISSPEPTIN; STEROID; GONADORELIN;

DISEASE COURSE; FEMALE; HUMAN; INCIDENCE; LUTEAL PHASE; OOCYTE MATURATION; OVARY HYPERSTIMULATION; PRIORITY JOURNAL; REVIEW; ADULT; ADVERSE EFFECTS; AGONISTS; DRUG EFFECTS; FERTILIZATION IN VITRO; IATROGENIC DISEASE; INFERTILITY, FEMALE; INTRACYTOPLASMIC SPERM INJECTION; METABOLISM; MORTALITY; OOCYTE; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION INDUCTION; PREGNANCY; PREGNANCY RATE; PROCEDURES; TREATMENT OUTCOME;

ADULT; CHORIONIC GONADOTROPIN; FEMALE; FERTILIZATION IN VITRO; GONADOTROPIN-RELEASING HORMONE; HUMANS; IATROGENIC DISEASE; INFERTILITY, FEMALE; KISSPEPTINS; OOCYTES; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION INDUCTION; PREGNANCY; PREGNANCY RATE; SPERM INJECTIONS, INTRACYTOPLASMIC; TREATMENT OUTCOME;

EID: 84929461323     PISSN: 1040872X     EISSN: 1473656X     Source Type: Journal    
DOI: 10.1097/GCO.0000000000000170     Document Type: Review

References (43)

1. Kupka MS, Ferraretti AP, de Mouzon J, et al. Assisted reproductive technology in Europe, 2010: results generated from European registers by ESHRE. Hum Reprod 2014; 10:2099-2113.
2. Braat DD, Schutte JM, Bernardus RE. Maternal death related to IVF in the Netherlands 1984-2008. Hum Reprod 2010; 25:1782-1786.
3. Edwards RG, Steptoe PC, Purdy JM. Establishing full-term human pregnancies using cleaving embryos grown in vitro. Br J Obstet Gynaecol 1980; 87:737-756.
4. Humaidan P, Kol S, Papanikolaou EG; Copenhagen GnRH agonist triggering Workshop Group. GnRH agonist for triggering of final oocyte maturation: time for a change of practice Hum Reprod Update 2011; 17:510-524.
5. Fauser BC, Devroey P. Reproductive biology and IVF: ovarian stimulation and luteal phase consequences. Trends Endocrinol Metab 2003; 14:236-242.
6. Tavaniotou A, Devroey P. Effect of human chorionic gonadotropin on luteal luteinizing hormone concentrations in natural cycles. Fertil Steril 2003; 80:654-655.
7. Tavaniotou A, Albano C, Smitz J, Devroey P. Comparison of LH concentrations in the early and mid-luteal phase in IVF cycles after treatment with HMG alone or in association with the GnRH antagonist Cetrorelix. Hum Reprod 2001; 16:663-667.
8. Macklon NS, Fauser BC. Impact of ovarian hyperstimulation on the luteal phase. J Reprod Fertil Suppl 2000; 55:101-108.
9. Humaidan P, Papanikolaou EG, Kyrou D, et al. The luteal phase after GnRHagonist triggering of ovulation: present and future perspectives. Reprod Biomed Online 2012; 24:134-141.
10. Humaidan P, Bredkjaer HE, Bungum L, et al. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Hum Reprod 2005; 20:1213-1220.
11. Kolibianakis EM, Schultze-Mosgau A, Schroer A, et al. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. Hum Reprod 2005; 20:2887-2892.
12. Humaidan P. Luteal phase rescue in high-risk OHSS patients by GnRHa triggering in combination with low-dose HCG: a pilot study. Reprod Biomed online 2009; 18:630-634.
13. Emperaire JC, Perneix I, Ruffie A. Luteal phase defects following agonisttriggered ovulation: a patient-dependent response. Reprod Biomed Online 2004; 9:22-27.
14. Humaidan P, Bredkjaer HE, Westergaard LG, Yding Andersen C. 1500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. Fertil Steril 2010; 93:847-854.
15. Papanikolaou EG, Pozzobon C, Kolibianakis EM, et al. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril 2006; 85:112-120.
16. Humaidan P, Polyzos NP, Alsbjerg B, et al. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multicentre studies in IVF patients. Hum Reprod 2013; 28:2511-2521.
17. Radesic B, Tremellen K. Oocyte maturation employing a GnRH agonist in combination with low-dose hCG luteal rescue minimizes the severity of ovarian hyperstimulation syndrome while maintaining excellent pregnancy rates. Hum Reprod 2011; 26:3437-3442.
18. Iliodromiti S, Blockeel C, Tremellen KP, et al. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study. Hum Reprod 2013; 28:2529-2536.
19. Engmann L, DiLuigi A, Schmidt D, et al. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril 2008; 89:84-91.
20. Iliodromiti S, Lan VT, Tuong HM, et al. Impact of GnRH agonist triggering and intensive luteal steroid support on live-birth rates and ovarian hyperstimulation syndrome: a retrospective cohort study. J Ovarian Res 2013; 6:93.
21. Imbar T, Kol S, Lossos F, et al. Reproductive outcome of fresh or frozenthawed embryo transfer is similar in high-risk patients for ovarian hyperstimulation syndrome using GnRH agonist for final oocyte maturation and intensive luteal support. Hum Reprod 2012; 27:753-759.
22. Babayof R, Margalioth EJ, Huleihel M, et al. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial. Hum Reprod 2006; 21:1260-1265.
23. Orvieto R. Intensive luteal-phase support with oestradiol and progesterone after GnRH-agonist triggering: does it help Reprod Biomed Online 2012; 24:680-681.
24. Griffin D, Benadiva C, Kummer N, et al. Dual trigger of oocyte maturation with gonadotropin-releasing hormone agonist and low-dose human chorionic gonadotropin to optimize live birth rates in high responders. Fertil Steril 2012; 97:1316-1320.
25. Shapiro BS, Daneshmand ST, Garner FC, et al. Gonadotropin-releasing hormone agonist combined with a reduced dose of human chorionic gonadotropin for final oocyte maturation in fresh autologous cycles of in vitro fertilization. Fertil Steril 2008; 90:231-233.
26. Shapiro BS, Daneshmand ST, Garner FC, et al. Comparison of 'triggers' using leuprolide acetate alone or in combination with low-dose human chorionic gonadotropin. Fertil Steril 2011; 95:2715-2717.
27. Humaidan P, Bungum L, Bungum M, Yding Andersen C. Rescue of corpus luteum function with peri-ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study. Reprod Biomed Online 2006; 13:173-178.
28. Devroey P, Polyzos NP, Blockeel C. An OHSS-free clinic by segmentation of IVF treatment. Hum Reprod 2011; 26:2593-2597.
29. Roque M, Lattes K, Serra S, et al. Fresh embryo transfer versus frozen embryo transfer in in vitro fertilization cycles: a systematic review and meta-analysis. Fertil Steril 2013; 99:156-162.
30. Tomas C, Alsbjerg B, Martikainen H, Humaidan P. Pregnancy loss after frozenembryo transfer: a comparison of three protocols. Fertil Steril 2012; 98:1165-1169.
31. Pinborg A, Loft A, Henningsen AK, Ziebe S. Does assisted reproductive treatment increase the risk of birth defects in the offspring Acta Obstet Gynecol Scand 2012; 91:1245-1246.
32. Belva F, Henriet S, Van den Abbeel E, et al. Neonatal outcome of 937 children born after transfer of cryopreserved embryos obtained by ICSI and IVF and comparison with outcome data of fresh ICSI and IVF cycles. Hum Reprod 2008; 23:2227-2238.
33. Fatemi HM, Popovic-Todorovic B, Humaidan P, et al. Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone (GnRH) agonist trigger and 'freeze-all' approach in GnRH antagonist protocol. Fertil Steril 2014; 101:1008-1011.
34. Ling LP, Phoon JW, Lau MS, et al. GnRH agonist trigger and ovarian hyperstimulation syndrome: relook at 'freeze-all strategy'. Reprod Biomed Online 2014; 29:392-394.
35. Gurbuz AS, Gode F, Ozcimen N, Isik AZ. Gonadotrophin-releasing hormone agonist trigger and freeze-all strategy does not prevent severe ovarian hyperstimulation syndrome: a report of three cases. Reprod Biomed Online 2014; 29:541-544.
36. Skorupskaite K, George JT, Anderson RA. The kisspeptin-GnRH pathway in human reproductive health and disease. Hum Reprod Update 2014; 20:485-500.
37. Millar RP, Newton CL. Current and future applications of GnRH, kisspeptin and neurokinin B analogues. Nat Rev Endocrinol 2013; 9:451-466.
38. Dhillo WS, Chaudhri OB, Patterson M, et al. Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males. J Clin Endocrinol Metab 2005; 12:6609-6615.
39. Jayasena CN, Comninos AN, Veldhuist JD, et al. A single injection of kisspeptin-54 temporarily increases luteinizing pulsatility in healthy women. Clin Endocrinol (Oxf) 2013; 79:558-563.
40. Jayasena CN, Abbara A, Velhuis JD, et al. Increasing LH pulsatility in women with hypothalamic amenorrhoea using intravenous infusion of Kisspeptin-54. J Clin Endocrinol Metab 2014; 99:953-961.
41. Jayasena CN, Abbara A, Comninos AN, et al. Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. J Clin Invest 2014; 124:3667-3677.
42. Jayasena CN, Comninos AN, Narayanaswamy S, et al. Acute and chonic effects of kisspeptin-54 administration on GH, prolactin and TSH secretion in healthy women. Clin Endocrinol (Oxf) 2014; 81:891-898.
43. Faucer BC, Jong D, Olivennes F, et al. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist Ganirelix during ovarian hyperstimulation for in vitro fertilization. J Clin Endocrinol Metab 2002; 87:709-715.